.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The DAWN trial changed the concept of the treatment window for mechanical thrombectomy in acute ischemic stroke. It enrolled selected patients with anterior-circulation large-vessel occlusion who presented between six and 24 hours after they were last known well and who had a clinical-core mismatch indicating potentially salvageable brain tissue. Patients assigned to thrombectomy plus standard medical therapy had substantially better functional outcomes than those receiving medical therapy alone. The trial demonstrated that time since symptom onset should not be interpreted in isolation when advanced imaging can identify patients with a favourable tissue profile. For HCPs, the practical message is to think in terms of physiology as well as chronology. Wake-up strokes and late-presenting patients may still benefit from thrombectomy when they satisfy appropriate clinical and imaging criteria. Rapid access to vascular imaging and transfer pathways therefore becomes part of the treatment itself. DAWN does not support indiscriminate thrombectomy beyond 6 hours; its lesson is that carefully selected patients can have substantial benefit even when the conventional time window has passed.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The DAWN trial changed the concept of the treatment window for mechanical thrombectomy in acute ischemic stroke. It enrolled selected patients with anterior-circulation large-vessel occlusion who presented between six and 24 hours after they were last known well and who had a clinical-core mismatch indicating potentially salvageable brain tissue. Patients assigned to thrombectomy plus standard medical therapy had substantially better functional outcomes than those receiving medical therapy alone. The trial demonstrated that time since symptom onset should not be interpreted in isolation when advanced imaging can identify patients with a favourable tissue profile. For HCPs, the practical message is to think in terms of physiology as well as chronology. Wake-up strokes and late-presenting patients may still benefit from thrombectomy when they satisfy appropriate clinical and imaging criteria. Rapid access to vascular imaging and transfer pathways therefore becomes part of the treatment itself. DAWN does not support indiscriminate thrombectomy beyond 6 hours; its lesson is that carefully selected patients can have substantial benefit even when the conventional time window has passed.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
